Hepatocellular cancer is the sixth most frequently diagnosed malignant disease worldwide,
and was responsible for tens of millions of deaths in 2020; however, treatment options for …

Hepatocellular carcinoma (HCC) is a leading cause of cancer-associated mortality
worldwide. HCC is an inflammation-associated immunogenic cancer that frequently arises in …

Background Hepatocellular carcinoma (HCC) remains one of the most common malignant
neoplasms. Lysophosphatidylcholine acyltransferase 1 (LPCAT1) plays a key role in the …

Abstract Objective Serine hydroxymethyltransferase 2 (SHMT2) is the first rate-limiting
enzyme for serine/glycine biosynthesis and one carbon metabolism. Here, we explore the …

Background The combination of immune checkpoint inhibitors (ICIs) and anti-angiogenic
agents has shown promising efficacy in unresectable hepatocellular carcinoma (HCC), but …

Acute myeloid leukemia (AML) with TP53 mutation is one of the most lethal cancers and
portends an extremely poor prognosis. Based on in silico analyses of druggable genes and …

Introduction Immune checkpoint blockade (ICB) is a systemic therapeutic option for
advanced hepatocellular carcinoma (HCC). However, low patient response rates …

Background The induction of ferroptosis and pyroptosis has been highlighted as a novel
approach to decide cancer cell fate. However, few studies have systematically explored the …

Backgrounds Liver hepatocellular carcinoma (HCC) is one of the most malignant tumors, of
which prognosis is unsatisfactory in most cases and metastatic of HCC often results in poor …

Hepatocellular carcinoma (HCC) is a prevalent primary liver cancer, representing
approximately 85% of cases. The diagnosis is often made in the middle and late stages …